Analysis of GPD1L mRNA levels in 17 hepatocellular carcinoma (HCC) cell lines in the GDSC1 database revealed a robust inverse correlation with therapeutic response, as measured by the half-maximal inhibitory concentration (IC50), for three therapeutic agents including PF-562271, Linsitinib, and BMS-754807 (Figure 4A,B). Here, GPD1L is linked to hepatocellular carcinoma.